Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G (2011). An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. Journal of Clinical Psychiatry
Andreasen NC, Carpenter WT Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry
Beck K, McCutcheon R, Bloomfield MA, Gaughran F, Reis Marques T, MacCabe J, Selvaraj S, Taylor D, Howes OD (2014). The practical management of refractory schizophrenia – the Maudsley Treatment REview and Assessment Team service approach. Acta Psychiatrica Scandinavica
Carbon M, Correll CU (2014). Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues in clinical neuroscience
Chouinard G (1991). Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophrenia Research
Chouinard G, Chouinard VA (2008). Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychotherapy and Psychosomatics
Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, McGuire PK (2014). Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biological Psychiatry
Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD (2012). Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. American Journal of Psychiatry
Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, Butt A, Stilo SA, Wiffen B, Powell J, Murray RM (2009). High-potency cannabis and the risk of psychosis. British Journal of Psychiatry
Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, Reis Marques T, Pariante C, Dazzan P, Mondelli V, Paparelli A, Kolliakou A, Prata D, Gaugrhan F, David AS, Morgan C, Sthal D, Khondoker M, MacCabe JH, Murray RM (2014). Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophrenia Bulletin
Emsley R, Nuamah I, Hough D, Gopal S (2012). Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophrenia Research
Frank J, Lang M, Witt SH, Strohmaier J, Rujescu D, Cichon S, Degenhardt F, Nothen MM, Collier DA, Ripke S, Naber D, Rietschel M (2015). Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. Molecular Psychiatry
Heinze G, Schemper M (2002). A solution to the problem of separation in logistic regression. Statistics in Medicine
Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D (2012). Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. British Journal of Psychiatry
Iyo M, Tadokoro S, Kanahara N, Hashimoto T, Niitsu T, Watanabe H, Hashimoto K (2013). Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. Journal of Clinical Psychopharmacology
Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin
Kolakowska T, Williams AO, Ardern M, Reveley MA, Jambor K, Gelder MG, Mandelbrote BM (1985). Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction. British Journal of Psychiatry
Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM (2014). Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophrenia Bulletin
Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB (2006). Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin
Lin CC, Wang YC, Chen JY, Liou YJ, Bai YM, Lai IC, Chen TT, Chiu HW, Li YC (2008). Artificial neural network prediction of clozapine response with combined pharmacogenetic and clinical data. Computer Methods and Programs in Biomedicine
Malla A, Norman R, Schmitz N, Manchanda R, Bechard-Evans L, Takhar J, Haricharan R (2006). Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychological Medicine
Mallett R, Leff J, Bhugra D, Pang D, Zhao JH (2002). Social environment, ethnicity and schizophrenia. A case-control study. Social Psychiatry and Psychiatric Epidemiology
Martin AK, Mowry B (2016). Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia. Psychological Medicine
McCutcheon R, Beck K, Bloomfield MA, Marques TR, Rogdaki M, Howes OD (2015). Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. Journal of Psychopharmacology
McGuffin P, Farmer A, Harvey I (1991). A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Archives of General Psychiatry
Meltzer HY (1997). Treatment-resistant schizophrenia–the role of clozapine. Current Medical Research and Opinion
Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, Thompson PA (1997). Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. American Journal of Psychiatry
Menezes NM, Arenovich T, Zipursky RB (2006). A systematic review of longitudinal outcome studies of first-episode psychosis. Psychological Medicine
Morgan C, Lappin J, Heslin M, Donoghue K, Lomas B, Reininghaus U, Onyejiaka A, Croudace T, Jones PB, Murray RM, Fearon P, Doody GA, Dazzan P (2014). Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study. Psychological Medicine
NICE (2014). Psychosis and Schizophrenia in Adults: Treatment and Management (Clinical Guideline 178). Royal College of Psychiatrists: London.
Nielsen J, Nielsen RE, Correll CU (2012
a). Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. Journal of Clinical Psychopharmacology
Nielsen J, Roge R, Schjerning O, Sorensen HJ, Taylor D (2012
b). Geographical and temporal variations in clozapine prescription for schizophrenia. European Neuropsychopharmacology
Ortiz BB, Araujo Filho GM, Araripe Neto AG, Medeiros D, Bressan RA (2013). Is disorganized schizophrenia a predictor of treatment resistance? Evidence from an observational study. Revista Brasileira de Psiquiatria
Revier CJ, Reininghaus U, Dutta R, Fearon P, Murray RM, Doody GA, Croudace T, Dazzan P, Heslin M, Onyejiaka A, Kravariti E, Lappin J, Lomas B, Kirkbride JB, Donoghue K, Morgan C, Jones PB (2015). Ten-year outcomes of first-episode psychoses in the MRC AESOP-10 study. Journal of Nervous and Mental Disease
Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA (1999). Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry
Ropcke B, Eggers C (2005). Early-onset schizophrenia: a 15-year follow-up. European Child & Adolescent Psychiatry
Sartorius N, Gulbinat W, Harrison G, Laska E, Siegel C (1996). Long-term follow-up of schizophrenia in 16 countries. A description of the International Study of Schizophrenia conducted by the World Health Organization. Social Psychiatry and Psychiatric Epidemiology
Schennach R, Riedel M, Musil R, Moller HJ (2012). Treatment Response in First-episode Schizophrenia. Clinical Psychopharmacology and Neuroscience
Schneider C, Papachristou E, Wimberley T, Gasse C, Dima D, MacCabe JH, Mortensen PB, Frangou S (2015). Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study. European Neuropsychopharmacology
Singh SP, Cooper JE, Fisher HL, Tarrant CJ, Lloyd T, Banjo J, Corfe S, Jones P (2005). Determining the chronology and components of psychosis onset: The Nottingham Onset Schedule (NOS). Schizophrenia Research
Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M (2014). Geographic and clinical variation in clozapine use in the United States. Psychiatric Services
Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M (2016). Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. American Journal of Psychiatry
Ucok A, Cikrikcili U, Karabulut S, Salaj A, Ozturk M, Tabak O, Durak R (2015). Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. International Clinical Psychopharmacology
Vanelle JM (1995). Treatment refractory schizophrenia [in French]. L'Encephale
21 (Spec. No. 3), 13–21.
Vanelle JM, Olie JP, Levy-Soussan P (1994). New antipsychotics in schizophrenia: the French experience. Acta Psychiatrica Scandinavica (Suppl.)
Vyas NS, Hadjulis M, Vourdas A, Byrne P, Frangou S (2007). The Maudsley early onset schizophrenia study. Predictors of psychosocial outcome at 4-year follow-up. European Child & Adolescent Psychiatry
Wechsler D (1997). Wechsler Adult Intelligence Scale. The Psychological Corporation: San Antonio, TX.
Wechsler D (2001). Wechsler Test of Adult Reading: WTAR. Psychological Corporation: San Antonio, TX.
Wheeler A, Humberstone V, Robinson G (2009). Outcomes for schizophrenia patients with clozapine treatment: how good does it get?
Journal of Psychopharmacology
WHO (1992). The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization: Geneva.
WHO (1994). Schedules for Clinical Assessment in Neuropsychiatry: Version 2: Manual. World Health Organization, Division of Mental Health: Geneva.
Wiersma D, Nienhuis FJ, Slooff CJ, Giel R (1998). Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophrenia Bulletin
Wimberley T, Støvring H, Sørensen HJ, Horsdal HT, MacCabe JH, Gasse C (2016). Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry